Consistent with this observation, a recent paper demonstrated that AKR1C3 was highly expressed in sorafenib-resistant HCC patients, and knockdown of AKR1C3 in HCC cell lines increased the sensitivity to sorafenib by inhibiting AKT activation [43]. Here, AKT1 is linked to hepatocellular carcinoma.